

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6392

Title: Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

Reviewer code: 02446043

Science editor: Cui, Xue-Mei

Date sent for review: 2013-10-16 16:14

Date reviewed: 2013-10-31 14:57

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The abstract should be rewritten : 1. Before using any initials, the full name must first be used, and the initials put in brackets eg entecavir (ETV). 2. Abstract should not have another subheading (Core Tip). Article should start with a subheading - Introduction. Article is otherwise reasonably well argued and referenced.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6392

Title: Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

Reviewer code: 00012513

Science editor: Cui, Xue-Mei

Date sent for review: 2013-10-16 16:14

Date reviewed: 2013-11-02 01:20

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

I believe that the review of Ezequiel RIDRUEJO represents an interesting update on the status of the art of treatment of HCV infection with first choice antiviral treatments Entecavir and Tenofovir. The manuscript is well documented and updated by what I think is interesting its publication. The unique relevant limitation is that it would be interesting the expansion of the final conclusion including a summary of the adverse side effects of greater relevance in both treatments, to facilitate physicians use in their daily work, and the comments or theories about the possible causes of not response taking into account the practical absence of antiviral resistences in both treatment.